Application of vitamin D and derivatives in hematological malignancies

详细信息	查看全文 | 推荐本文 |

• 作者：Minji Kim^a ; Leonardo Mirandola^a ; ^d ; Apurva Pandey^a ; ^{betibiharki@gmail.com} ; Diane D. Nguyen^a ; Marjorie R. Jenkins^a ; ^b ; ^c ; ^d ; Meryem Turcel^e ; Everardo Cobos^a ; ^d ; Maurizio Chiriva-Internati^a ; ^d ; ^{maurizio.chiriva@ttuhsc.edu}
• 关键词：MDS ; myelodysplastic syndrome (preleukemia) ; AML ; acute myelogenous leukemia ; CML ; chronic myelogenous leukemia ; CMML ; chronic myelomonocytic leukemia ; NHL ; non-Hodgkin&rsquo ; s lymphoma
• 刊名：Cancer Letters
• 出版年：2012
• 期刊代码：44_03043835
• 类别：med
• 出版时间：1 June, 2012
• 卷：319
• 期：1
• 页码：8-22
• 文件大小：1010 K

摘要

The role of vitamin D in the inhibition of malignant cell proliferation in hematological malignancies is indicative of its future use in cancer therapy. An understanding of the biochemical mechanism by which vitamin D and its derivatives exert their effects will prove to be useful in the development of clinically applicable therapies involving vitamin D. While the use of vitamin D in clinical trials against acute myeloid leukemia and myelodysplastic syndrome has been met with few successes thus far, in vitro and in vivo studies as well as epidemiological correlations between vitamin D deficiency and cancer have implicated the great potential of the use of vitamin D derivatives in effective therapies against neoplastic diseases. For these reasons, a focus on current understanding of role of vitamin D and derivatives in hematologic malignancies is relevant and the goal for this review.